查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1949577

胃腸道非處方藥市場－全球產業規模、佔有率、趨勢、機會及預測（按藥物類別、適應症、最終用戶、地區和競爭格局分類，2021-2031年）

Gastrointestinal OTC Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug Class, By Indication, By End User, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球消化器官系統胃腸道藥物市場預計將從 2025 年的 415.1 億美元成長到 2031 年的 608.8 億美元，複合年成長率為 6.59%。

該市場主要由非處方箋藥品組成，旨在無需醫療干預即可緩解便秘、腹瀉和胃食道逆流等消化器官系統症狀。推動這一市場成長的關鍵因素包括全球人口老化，導致慢性消化系統疾病需要持續管理，以及生活方式相關消化器官系統疾病的日益普遍。此外，世界各地的醫療保健系統都在推廣自我管理策略，以降低營運成本並減輕基層醫療服務的壓力。這一市場的需求規模龐大；根據歐洲自我護理產業委員會 (AESC) 的報告，到 2024 年，歐洲將售出 47 億盒非處方藥，用於治療包括消化系統疾病在內的輕微健康問題。

市場概覽
預測期 2027-2031
市場規模：2025年 415.1億美元
市場規模：2031年 608.8億美元
複合年成長率：2026-2031年 6.59%
成長最快的細分市場 質子幫浦阻斷劑
最大的市場 北美洲

儘管存在這些成長要素，但由於產品安全和標籤方面的嚴格法規結構，市場仍面臨許多挑戰。監管機構執行旨在保護消費者和防止不良反應的嚴格標準，這可能會延緩新配方的核准，並增加生產商的合規成本。這種嚴格的審查構成重大挑戰，提高了市場准入門檻，並可能減緩全球非處方胃腸道藥物行業的創新速度。

市場促進因素

常見胃腸道疾病的日益普遍是全球消化器官系統成藥市場的主要促進因素。疫情後生活方式的改變加重了胃腸道疾病的負擔，使得人們迫切需要便捷的治療方法來緩解大腸激躁症（IBS）和消化不良等症狀。這種日益成長的趨勢促使消費者避免就醫的繁瑣，轉而尋求處方箋以獲得即時緩解。例如，2025年7月發表在《臨床胃腸病學和肝病學》雜誌上的一項研究發現，成人功能性消化不良的盛行率從疫情前的8.3%上升到疫情後的11.9%，凸顯了人們對有效消化器官系統治療方法日益成長的需求。

市場擴張的進一步驅動力在於消費者對預防性醫療保健和自我治療的日益重視。隨著人們對自身健康採取更加積極主動的態度，非處方藥在緩解輕微胃腸道症狀方面的應用日益增多，這主要得益於值得信賴的品牌產品供應量的增加以及處方藥重新歸類為非處方藥（OTC）。根據Haleon公司於2025年2月發布的2024年度報告，該公司消化健康及其他業務部門實現了5.5%的內部成長，營收達到20億英鎊，這主要得益於產品創新。這一趨勢也與更廣泛的健康行為相符。根據STADA於2025年6月發布的2025年健康報告，目前66%的歐洲人會定期進行大部分預防性體檢，這意味著積極參與健康管理的人數增加了5個百分點，有利於自我護理領域的發展。

市場挑戰

嚴格的產品標籤和安全法規結構對全球非處方胃腸成藥市場的成長構成了重大障礙。雖然這些嚴格的標準對於保護消費者至關重要，但它們也給製造商帶來了沉重的營運負擔，因為新配方需要進行大量的臨床試驗和複雜的核准流程。高昂的成本和漫長的合規流程抑制了對新型胃腸道治療藥物的投資，有效地延緩了針對消化不良和胃灼熱等症狀的創新緩解措施的推出。因此，製造商被迫將資源從研發轉移到合規，這提高了小型企業的進入門檻，並阻礙了市場動態。

監管產品的龐大數量凸顯了營運挑戰的規模。 2024年，歐洲自我護理產業協會報告稱，該產業管理超過4,000種非處方藥，這些藥品由200多種活性藥物成分製成。如此龐大的產品範圍需要持續不斷的監管回應，即使是標籤或安全評估的微小更新也會影響數千種產品線。這種監管密度直接阻礙了市場的靈活性，使企業難以快速回應胃腸道領域不斷變化的消費者需求。

市場趨勢

益生元和益生菌腸道健康補充劑的流行正在重塑市場格局，這主要歸功於消費者日益關注最佳化腸道菌群以維持長期健康。這一趨勢已超越了基礎的消化緩解，發展到透過腸道生物調節來改善特定健康狀況（例如免疫系統支持和功能性腸道疾病）的高級配方。製造商們積極回應，透過推出經臨床檢驗、菌株特異性和高活性的產品，將這一品類提升到超越一般健康範疇的水平。這種轉變也體現在專業公司的財務表現。根據BioGaia於2025年2月發布的“2024年1月至12月財務業績報告”，該公司成人健康領域的年度淨銷售額預計將成長17%，這表明全球對靶向益生菌解決方案的需求強勁。

同時，消費者對「潔淨標示」產品（而非合成藥物）的偏好日益成長，推動了天然草本助消化劑的普及。消費者越來越傾向於選擇薄荷、生薑和薑黃等植物成分，這些成分以其溫和的功效和較少的副作用而聞名。這種需求促使非處方藥生產商擴大其草本產品線，並改善現有產品線以吸引注重整體健康的消費者。 《全食雜誌》（WholeFoods Magazine）在其2025年2月刊中援引「CRN 2024消費者調查亮點」報道稱，生薑作為助消化劑的使用率已上升至膳食補充劑使用者的13%，這印證了上述趨勢。這表明，傳統的植物療法正逐漸融入現代人的日常自我護理習慣中。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球非處方胃腸道藥物市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 依藥物類別（瀉藥、胃腸道癌症治療藥物、胃酸分泌抑制劑、止瀉藥、質子幫浦阻斷劑、H2受體拮抗劑、胃酸中和劑、腸道抗發炎藥、止吐藥）
    • 根據適應症（胃食道逆流或灼熱、便秘、腹瀉、暈動病、其他）
    • 依最終用戶（醫院藥局、零售藥局、網路藥局、其他）分類
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

6. 北美非處方胃腸道藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國家分析
    • 美國
    • 加拿大
    • 墨西哥

7. 歐洲非處方胃腸道藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國家分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

8. 亞太地區非處方胃腸道藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

9. 中東和非洲胃腸道非處方藥市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東和非洲：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

10. 南美洲非處方胃腸道藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國家分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進要素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 最新進展

第13章 全球非處方胃腸道藥物市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的可能性
  • 供應商電力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Viatris Inc.
  • Sandoz Group AG
  • Johnson & Johnson Services, Inc.
  • Sun Pharmaceuticals Industries Limited
  • Teva Pharmaceuticals Industries Ltd.
  • Zydus Life science Ltd.
  • Sanofi SA
  • Bayer AG
  • Pfizer Inc.
  • GlaxoSmithKline Plc.

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 17601

The Global Gastrointestinal OTC Drugs Market is projected to expand from USD 41.51 Billion in 2025 to USD 60.88 Billion by 2031, reflecting a CAGR of 6.59%. This market consists of non-prescription pharmaceutical formulations aimed at relieving digestive issues such as constipation, diarrhea, and gastroesophageal reflux disease without the need for a doctor's intervention. Key drivers of this growth include an aging global population requiring consistent management of chronic gastrointestinal conditions and the increasing prevalence of lifestyle-related digestive disorders. Additionally, healthcare systems around the world are promoting self-medication strategies to lower operational expenses and decrease the strain on primary care services. The magnitude of this demand is significant; the Association of the European Self-Care Industry reported that 4.7 billion packs of non-prescription medicines were sold in Europe in 2024 to address minor health concerns, including gastrointestinal ailments.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 41.51 Billion
Market Size 2031USD 60.88 Billion
CAGR 2026-20316.59%
Fastest Growing SegmentProton Pump Inhibitors
Largest MarketNorth America

Despite these positive growth factors, the market encounters substantial obstacles due to strict regulatory frameworks concerning product safety and labeling. Regulatory authorities implement rigorous standards to ensure consumer protection and prevent adverse effects, a process that can prolong the approval of new formulations and escalate compliance costs for producers. This intense scrutiny serves as a major challenge, establishing high barriers to entry and potentially retarding the rate of innovation within the global gastrointestinal OTC industry.

Market Driver

The increasing prevalence of common gastrointestinal disorders acts as a major catalyst for the Global Gastrointestinal OTC Drugs Market. Lifestyle changes following the pandemic have intensified the burden of digestive ailments, creating a need for accessible treatments for conditions like irritable bowel syndrome (IBS) and indigestion. This rising incidence drives consumers to seek immediate relief through non-prescription avenues, avoiding the logistical challenges of clinical appointments. For example, a study published in Clinical Gastroenterology and Hepatology in July 2025 indicated that the prevalence of functional dyspepsia in adults rose from 8.3% before the pandemic to 11.9% afterward, highlighting the growing demand for effective digestive remedies.

Market expansion is further fueled by a growing consumer preference for preventive care and self-medication. As individuals take a more proactive approach to their health, the use of over-the-counter treatments for minor gastric issues has increased, supported by the greater availability of trusted brands and the reclassification of prescription drugs to OTC status. According to Haleon's 'Annual Report 2024', released in February 2025, the company's Digestive Health and Other segment achieved £2.0 billion in revenue with 5.5% organic growth, driven by product innovation. This trend is consistent with broader health behaviors; the 'STADA Health Report 2025', published in June 2025, noted that 66% of Europeans now attend most of their preventive checkups, reflecting a 5 percentage point rise in proactive health engagement that benefits the self-care sector.

Market Challenge

Rigorous regulatory frameworks regarding product labeling and safety present a significant barrier to the growth of the Global Gastrointestinal OTC Drugs Market. These strict standards, while necessary for consumer protection, place heavy operational demands on manufacturers by requiring extensive clinical testing and complex approval processes for new formulations. The substantial costs and lengthy timelines involved in meeting compliance requirements discourage investment in novel gastrointestinal therapies, effectively delaying the introduction of innovative relief options for conditions such as indigestion and heartburn. Consequently, manufacturers often must redirect resources from research and development to regulatory compliance, creating high entry barriers for smaller firms and stifling market dynamism.

The magnitude of this operational challenge is underscored by the vast volume of products subject to such oversight. In 2024, the Association of the European Self-Care Industry reported that the sector managed over 4,000 non-prescription medicines derived from more than 200 different active pharmaceutical ingredients. This extensive portfolio necessitates continuous regulatory maintenance, where even minor updates to labeling or safety evaluations can impact thousands of product lines. Such regulatory density directly hinders the market's agility, making it difficult for companies to respond quickly to evolving consumer needs within the gastrointestinal sector.

Market Trends

The market is being reshaped by the proliferation of prebiotic and probiotic gut health supplements, as consumers increasingly prioritize microbiome optimization for long-term wellness. This trend extends beyond basic digestive relief toward advanced formulations designed to address specific conditions, such as immune system support and functional bowel disorders, through gut modulation. Manufacturers are reacting by introducing strain-specific, high-potency products with clinical validation, thereby elevating the segment above general wellness. This shift is reflected in the financial results of specialized firms; according to BioGaia's 'Year-end report January - December 2024', published in February 2025, net sales in the company's Adult Health segment rose by 17% for the year, demonstrating strong global demand for targeted probiotic solutions.

Simultaneously, there is a rising consumer preference for natural and herbal digestive remedies, driven by a demand for "clean label" alternatives to synthetic drugs. Shoppers are actively seeking plant-based ingredients like peppermint, ginger, and turmeric, known for their minimal side effects and gentle efficacy. This demand is prompting OTC manufacturers to launch herbal adjacencies or reformulate existing lines to attract holistic-minded consumers. Validating this trend, WholeFoods Magazine reported in February 2025, citing 'Highlights from CRN's 2024 Consumer Survey', that usage of ginger as a digestive aid increased to 13% among supplement users, indicating the growing integration of traditional botanical solutions into modern self-care regimens.

Key Market Players

  • Viatris Inc.
  • Sandoz Group AG
  • Johnson & Johnson Services, Inc.
  • Sun Pharmaceuticals Industries Limited
  • Teva Pharmaceuticals Industries Ltd.
  • Zydus Life science Ltd.
  • Sanofi SA
  • Bayer AG
  • Pfizer Inc.
  • GlaxoSmithKline Plc.

Report Scope

In this report, the Global Gastrointestinal OTC Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Gastrointestinal OTC Drugs Market, By Drug Class

  • Laxatives
  • Gastrointestinal Cancer Treatments
  • Gastric Acid Reducers
  • Anti-Diarrheal
  • Proton Pump Inhibitors
  • H2 Inhibitors
  • Gastric Acid Neutralizers
  • Bowel Anti-Inflammatory
  • Anti-Emetics

Gastrointestinal OTC Drugs Market, By Indication

  • Gastroesophageal Reflux Disease or Heartburn
  • Constipation
  • Diarrhea
  • Motion Sickness
  • Others

Gastrointestinal OTC Drugs Market, By End User

  • Hospitals Pharmacies
  • Retail Pharmacies
  • Online pharmacies
  • Others

Gastrointestinal OTC Drugs Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Gastrointestinal OTC Drugs Market.

Available Customizations:

Global Gastrointestinal OTC Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Gastrointestinal OTC Drugs Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Drug Class (Laxatives, Gastrointestinal Cancer Treatments, Gastric Acid Reducers, Anti-Diarrheal, Proton Pump Inhibitors, H2 Inhibitors, Gastric Acid Neutralizers, Bowel Anti-Inflammatory, Anti-Emetics)
    • 5.2.2. By Indication (Gastroesophageal Reflux Disease or Heartburn, Constipation, Diarrhea, Motion Sickness, Others)
    • 5.2.3. By End User (Hospitals Pharmacies, Retail Pharmacies, Online pharmacies, Others)
    • 5.2.4. By Region
    • 5.2.5. By Company (2025)
  • 5.3. Market Map

6. North America Gastrointestinal OTC Drugs Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Drug Class
    • 6.2.2. By Indication
    • 6.2.3. By End User
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Gastrointestinal OTC Drugs Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Drug Class
        • 6.3.1.2.2. By Indication
        • 6.3.1.2.3. By End User
    • 6.3.2. Canada Gastrointestinal OTC Drugs Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Drug Class
        • 6.3.2.2.2. By Indication
        • 6.3.2.2.3. By End User
    • 6.3.3. Mexico Gastrointestinal OTC Drugs Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Drug Class
        • 6.3.3.2.2. By Indication
        • 6.3.3.2.3. By End User

7. Europe Gastrointestinal OTC Drugs Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Drug Class
    • 7.2.2. By Indication
    • 7.2.3. By End User
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Gastrointestinal OTC Drugs Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Drug Class
        • 7.3.1.2.2. By Indication
        • 7.3.1.2.3. By End User
    • 7.3.2. France Gastrointestinal OTC Drugs Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Drug Class
        • 7.3.2.2.2. By Indication
        • 7.3.2.2.3. By End User
    • 7.3.3. United Kingdom Gastrointestinal OTC Drugs Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Drug Class
        • 7.3.3.2.2. By Indication
        • 7.3.3.2.3. By End User
    • 7.3.4. Italy Gastrointestinal OTC Drugs Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Drug Class
        • 7.3.4.2.2. By Indication
        • 7.3.4.2.3. By End User
    • 7.3.5. Spain Gastrointestinal OTC Drugs Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Drug Class
        • 7.3.5.2.2. By Indication
        • 7.3.5.2.3. By End User

8. Asia Pacific Gastrointestinal OTC Drugs Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Drug Class
    • 8.2.2. By Indication
    • 8.2.3. By End User
    • 8.2.4. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Gastrointestinal OTC Drugs Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Drug Class
        • 8.3.1.2.2. By Indication
        • 8.3.1.2.3. By End User
    • 8.3.2. India Gastrointestinal OTC Drugs Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Drug Class
        • 8.3.2.2.2. By Indication
        • 8.3.2.2.3. By End User
    • 8.3.3. Japan Gastrointestinal OTC Drugs Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Drug Class
        • 8.3.3.2.2. By Indication
        • 8.3.3.2.3. By End User
    • 8.3.4. South Korea Gastrointestinal OTC Drugs Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Drug Class
        • 8.3.4.2.2. By Indication
        • 8.3.4.2.3. By End User
    • 8.3.5. Australia Gastrointestinal OTC Drugs Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Drug Class
        • 8.3.5.2.2. By Indication
        • 8.3.5.2.3. By End User

9. Middle East & Africa Gastrointestinal OTC Drugs Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Drug Class
    • 9.2.2. By Indication
    • 9.2.3. By End User
    • 9.2.4. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Gastrointestinal OTC Drugs Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Drug Class
        • 9.3.1.2.2. By Indication
        • 9.3.1.2.3. By End User
    • 9.3.2. UAE Gastrointestinal OTC Drugs Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Drug Class
        • 9.3.2.2.2. By Indication
        • 9.3.2.2.3. By End User
    • 9.3.3. South Africa Gastrointestinal OTC Drugs Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Drug Class
        • 9.3.3.2.2. By Indication
        • 9.3.3.2.3. By End User

10. South America Gastrointestinal OTC Drugs Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Drug Class
    • 10.2.2. By Indication
    • 10.2.3. By End User
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Gastrointestinal OTC Drugs Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Drug Class
        • 10.3.1.2.2. By Indication
        • 10.3.1.2.3. By End User
    • 10.3.2. Colombia Gastrointestinal OTC Drugs Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Drug Class
        • 10.3.2.2.2. By Indication
        • 10.3.2.2.3. By End User
    • 10.3.3. Argentina Gastrointestinal OTC Drugs Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Drug Class
        • 10.3.3.2.2. By Indication
        • 10.3.3.2.3. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Gastrointestinal OTC Drugs Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Viatris Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Sandoz Group AG
  • 15.3. Johnson & Johnson Services, Inc.
  • 15.4. Sun Pharmaceuticals Industries Limited
  • 15.5. Teva Pharmaceuticals Industries Ltd.
  • 15.6. Zydus Life science Ltd.
  • 15.7. Sanofi SA
  • 15.8. Bayer AG
  • 15.9. Pfizer Inc.
  • 15.10. GlaxoSmithKline Plc.

16. Strategic Recommendations

17. About Us & Disclaimer